Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b

Neurology
N H PliskinB G Arnason

Abstract

We assessed neuropsychological function longitudinally in 30 MS patients who participated in the pivotal trial of interferon beta-1b (IFN-beta-1b). Nine patients received high-dose IFN-beta-1b (8.0 million units), eight low-dose IFN-beta-1b (1.6 MIU), and 13 placebo. There was significant improvement in Wechsler Memory Scale Visual Reproduction-Delayed Recall scores between years 2 and 4 of the trial in MS subjects receiving high-dose IFN-beta-1b. Motoric performance, MRI lesion area, and depression rating scores did not correlate with this finding. Comparison of MRI at baseline and at years 2 and 4 revealed significant changes over time for the total cohort (p < 0.02). Mean lesion area in the high-dose group did not change over time, whereas the low-dose and placebo groups had increases in total lesion area of 28 and 36%, respectively, at year 4. Expanded disability status scale scores did not change significantly between years 2 and 4 of the trial, nor did they correlate with MRI lesion area at any assessment point. We conclude that high-dose IFN-beta-1b improves delayed visual reproduction test performance in MS patients, a finding unlikely to be explained by practice effects or brain lesion area.

Citations

Mar 15, 2005·Der Nervenarzt·C EngelU K Zettl
Sep 20, 2005·Journal of Neurology·Barry G W Arnason
May 16, 2007·Journal of Neurology·Alexander WinkelmannUwe K Zettl
Nov 28, 2012·Journal of Neurology·Maria Pia AmatoGiancarlo Comi
Sep 28, 2010·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Flavia MattioliR Capra
Oct 23, 2010·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Giancarlo Comi
Jul 14, 2012·Current Neurology and Neuroscience Reports·Jesus Lovera, Blake Kovner
May 17, 2005·Physical Medicine and Rehabilitation Clinics of North America·Jack S Burks
May 17, 2005·Physical Medicine and Rehabilitation Clinics of North America·Mary Pepping, Dawn M Ehde
May 9, 2002·Journal of the Neurological Sciences·Douglas R Jeffery
Jul 30, 1999·Journal of Neuroimmunology·D BourdetteE Montgomery
Nov 11, 1999·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·B G Arnason
Sep 26, 2013·Journal of the International Neuropsychological Society : JINS·Jose M LafosseChristopher M Filley
May 7, 2010·Journal of Clinical and Experimental Neuropsychology·Michael R BassoTaeh Ward
Sep 3, 1998·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·B G Arnason, F Dianzani
Oct 13, 2012·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·E PortaccioM P Amato
Mar 12, 1999·Annual Review of Medicine·B G Arnason
Feb 26, 2010·Annals of Indian Academy of Neurology·Jack S BurksHarry Haydon Hill
Nov 19, 2011·Multiple Sclerosis International·Mona Alkhawajah, Joel Oger
Aug 2, 2014·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Anthony T Reder, Xuan Feng
Mar 17, 2007·Journal of Clinical and Experimental Neuropsychology·Jose M LafosseChristopher M Filley
Oct 15, 2010·The International Journal of Neuroscience·Maria MelansonMichael Namaka
Feb 18, 2016·CNS Drugs·Shumita RoyBianca Weinstock-Guttman
Mar 18, 2010·International Review of Psychiatry·Lambros MessinisPanagiotis Papathanasopoulos
Mar 18, 2010·International Review of Psychiatry·Odysseas KargiotisPanagiotis Papathanasopoulos
Mar 13, 2010·International Review of Psychiatry·Epameinondas LyrosPanagiotis Papathanasopoulos
Jun 9, 2005·Expert Review of Neurotherapeutics·Scott B Patten
Nov 3, 2006·Expert Review of Neurotherapeutics·Stephanie H Ameis, Anthony Feinstein
Apr 28, 2005·Expert Review of Neurotherapeutics·Magnhild Sandberg-Wollheim
Oct 22, 2008·Expert Review of Neurotherapeutics·Maria Pia AmatoEmilio Portaccio
Aug 11, 2012·Expert Opinion on Investigational Drugs·Francesco Patti
Mar 29, 2011·Neurologic Clinics·Tanuja ChitnisEmmanuelle Waubant
Mar 29, 2011·Neurologic Clinics·Laura J Julian
Nov 15, 2008·Lancet Neurology·Nancy D Chiaravalloti, John DeLuca
Jul 9, 2004·Journal of the Neurological Sciences·Alessandra SolariUNKNOWN CRIMS Trial
Jun 6, 2006·Clinical Therapeutics·Heidi J Crayton, Howard S Rossman
May 9, 2006·Journal of the Neurological Sciences·Eric Sartori, Gilles Edan
Apr 22, 2006·Journal of the Neurological Sciences·Christopher ChristodoulouLauren B Krupp
Apr 22, 2006·Journal of the Neurological Sciences·X Montalban, J Rio
Apr 22, 2006·Journal of the Neurological Sciences·Roberta LanzilloVincenzo Brescia Morra
Apr 29, 2006·Journal of the Neurological Sciences·Maria Pia AmatoValentina Zipoli
May 16, 2006·Journal of the Neurological Sciences·I MagnanoM R Piras

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.